NasdaqCM:MLTXBiotechs
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions
MoonLake Immunotherapeutics (NasdaqCM:MLTX) is back in focus after fresh FDA feedback allowed the company to move ahead with a Biologics License Application for Sonelokimab in hidradenitis suppurativa using existing trial data.
See our latest analysis for MoonLake Immunotherapeutics.
The FDA update has arrived after a volatile stretch for MoonLake, with a 30 day share price return of 25.17% and a 90 day share price return of 79.16%, even as the 1 year total shareholder return sits at a 61.74%...